BioMarin Kills Kyndrisa, But Duchenne Pursuit Not Over
Executive Summary
Seeing no clear path to approval in the US or Europe for its Duchenne muscular dystrophy drug Kyndrisa (drisapersen), BioMarin Pharmaceutical Inc. has decided to shelve the experimental medicine, along with three other first-generation follow-on products. But it said its Duchenne pursuit is not completely over, declaring it continues to "explore" its early-stage next-generation oligonucleotides as potential treatments for the disease, which generally kills patients before they reach 30 years.
You may also be interested in...
Deal Watch: Novartis Signs Deals In Migraine & Diabetes
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.
Santhera Setback Could Have Wide-Reaching Effects For DMD Drugs
The DMD community faces another setback as FDA pushes back timelines for Santhera and its respiratory drug, pushing the market to question what will come for other DMD treatments in development.